Melnikov Mikhail, Kasatkin Dmitriy, Lopatina Anna, Spirin Nikolay, Boyko Alexey, Pashenkov Mikhail
Department of Neuroimmunology, Federal Center of Brain Research and Neurotechnology of the Federal Medical-Biological Agency of Russia, Moscow, Russia.
Department of Neurology, Neurosurgery and Medical Genetics, Pirogov Russian National Research Medical University, Moscow, Russia.
Front Neurol. 2022 Jul 22;13:920408. doi: 10.3389/fneur.2022.920408. eCollection 2022.
Investigation of neuroimmune interactions is one of the most developing areas in the study of multiple sclerosis pathogenesis. Recent evidence suggests the possibility of modulating neuroinflammation by targeting biogenic amine receptors. It has been shown that selective serotonin reuptake inhibitor fluoxetine modulates innate and adaptive immune system cells' function and can reduce experimental autoimmune encephalomyelitis and multiple sclerosis severity. This brief report discusses the immune mechanisms underlying the multiple sclerosis pathogenesis and the influence of fluoxetine on them. The retrospective data on the impact of fluoxetine treatment on the course of multiple sclerosis are also presented. The results of this and other studies suggest that fluoxetine could be considered an additional therapy to the standard first-line disease-modifying treatment for relapsing-remitting multiple sclerosis.
神经免疫相互作用的研究是多发性硬化症发病机制研究中发展最为迅速的领域之一。最近的证据表明，通过靶向生物胺受体来调节神经炎症具有可能性。已经表明，选择性5-羟色胺再摄取抑制剂氟西汀可调节先天性和适应性免疫系统细胞的功能，并能减轻实验性自身免疫性脑脊髓炎和多发性硬化症的严重程度。本简要报告讨论了多发性硬化症发病机制背后的免疫机制以及氟西汀对它们的影响。还介绍了氟西汀治疗对多发性硬化症病程影响的回顾性数据。本研究及其他研究的结果表明，对于复发缓解型多发性硬化症，氟西汀可被视为标准一线疾病修饰治疗之外的一种附加疗法。
